Clinical Trials Browser

Has results × Bendamustine Hydrochloride × Plasma cell × Clear all

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

24 enrolled 13 charts

Multiple Myeloma

NCT03187223 2025-01-30

BEB-2

Phase 2 Completed

120 enrolled 11 charts

Multiple Myeloma

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Phase 1/2 Terminated

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02148913 2024-07-26

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

Phase 1 Completed

18 enrolled 10 charts

Multiple Myeloma

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Multiple Myeloma

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02477215 2020-10-22

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

38 enrolled 18 charts

Multiple Myeloma

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Phase 2 Terminated

11 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01049945 2020-02-11

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

70 enrolled 11 charts

Multiple Myeloma

NCT00916058 2019-06-04

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Phase 1/2 Completed

57 enrolled 19 charts

Multiple Myeloma

NCT01484626 2018-07-10

BVRD

Phase 1/2 Terminated

3 enrolled 4 charts

Multiple Myeloma

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2 Terminated

24 enrolled 3 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2 Completed

43 enrolled 5 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01056276 2017-05-03

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Phase 2 Completed

59 enrolled 9 charts

Multiple Myeloma

NCT00920855 2012-10-04

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

40 enrolled 16 charts

Multiple Myeloma